Relmada Therapeutics, Inc.

NasdaqGS:RLMD Voorraadrapport

Marktkapitalisatie: US$102.6m

Relmada Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Relmada Therapeutics is Sergio Traversa, benoemd in Apr2012, heeft een ambtstermijn van 12.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.78M, bestaande uit 14.7% salaris en 85.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.27% van de aandelen van het bedrijf, ter waarde $ 1.31M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 4.8 jaar.

Belangrijke informatie

Sergio Traversa

Algemeen directeur

US$4.8m

Totale compensatie

Percentage CEO-salaris14.7%
Dienstverband CEO12.6yrs
Eigendom CEO1.3%
Management gemiddelde ambtstermijn4.8yrs
Gemiddelde ambtstermijn bestuur4.8yrs

Recente managementupdates

Recent updates

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Mar 21

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 13
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Jan 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Dec 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Aug 29
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

May 07
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Dec 15
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Oct 14

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Sep 14

Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression

Aug 09

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Jul 14
We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

4 Clinical Catalysts On Tap For Relmada In 2022

Jan 28

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Nov 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Our First Look At Relmada Therapeutics

Jun 28

We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Jun 28
We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 09
Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Jan 15
What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017

Dec 07

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Dec 02

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Nov 16

Analyse CEO-vergoeding

Hoe is Sergio Traversa's beloning veranderd ten opzichte van Relmada Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$94m

Dec 31 2023US$5mUS$701k

-US$99m

Sep 30 2023n/an/a

-US$112m

Jun 30 2023n/an/a

-US$129m

Mar 31 2023n/an/a

-US$144m

Dec 31 2022US$3mUS$668k

-US$157m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$157m

Mar 31 2022n/an/a

-US$143m

Dec 31 2021US$36mUS$630k

-US$126m

Sep 30 2021n/an/a

-US$112m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$71m

Dec 31 2020US$900kUS$600k

-US$59m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$16mUS$214k

-US$15m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018n/an/a

-US$17m

Sep 30 2018n/an/a

-US$11m

Jun 30 2018US$975kUS$376k

-US$9m

Compensatie versus markt: De totale vergoeding ($USD 4.78M ) Sergio } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 651.15K ).

Compensatie versus inkomsten: De vergoeding van Sergio is gestegen terwijl het bedrijf verliesgevend is.


CEO

Sergio Traversa (64 yo)

12.6yrs

Tenure

US$4,778,944

Compensatie

Dr. Sergio Traversa, PharmD, MBA has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relmada Th...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Sergio Traversa
CEO & Director12.6yrsUS$4.78m1.27%
$ 1.3m
Maged Shenouda
Chief Financial Officer4.8yrsUS$2.34m0.29%
$ 300.3k
Charles Ence
Chief Accounting & Compliance Officer4.8yrsUS$2.33m0.13%
$ 132.5k
Paolo Manfredi
Chief Scientific Officer4.1yrsgeen gegevensgeen gegevens
Gina DiGuglielmo
VP & Head of Clinical Operations5.6yrsgeen gegevensgeen gegevens
Marco Pappagallo
Chief Clinical Officer4.1yrsgeen gegevensgeen gegevens
John Hixon
Head of Commercial2.3yrsgeen gegevensgeen gegevens
Andrew Cutler
Senior Clinical Development Advisorno datageen gegevensgeen gegevens
Richard Mangano
Consultant7.6yrsgeen gegevensgeen gegevens

4.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RLMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Sergio Traversa
CEO & Director12.6yrsUS$4.78m1.27%
$ 1.3m
Maged Shenouda
Chief Financial Officer4.8yrsUS$2.34m0.29%
$ 300.3k
Charles Casamento
Independent Chairman of the Board9.3yrsUS$674.90k0%
$ 0
Stephen Stahl
Member of Scientific Advisory Board4.8yrsgeen gegevensgeen gegevens
Maurizio Fava
Member of Scientific Advisory Board7.4yrsgeen gegevensgeen gegevens
Fabiana Fedeli
Independent Director1.8yrsUS$1.33m0%
$ 0
Paul Kelly
Director9yrsUS$1.67m0.70%
$ 721.8k
Charles Inturrisi
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
John Glasspool
Independent Director4.9yrsUS$604.77kgeen gegevens
Luca Pani
Member of Scientific Advisory Board4.8yrsgeen gegevensgeen gegevens
Dan Iosifescu
Member of Scientific Advisory Board4.8yrsgeen gegevensgeen gegevens
Sanjay Mathew
Member of Scientific Advisory Board4.8yrsgeen gegevensgeen gegevens

4.8yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RLMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).